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Sugar pills are usually placebos, but Smith et al. (2002,
this issue) use one to rescue designer mice unable to make
GDP-Fucose. Dietary fucose enters a salvage pathway and
spares the mice. Sound simple? Not so. Unknown genetic
factors determine life or death.
 
Fucosylated sugar chains decorate cell surface glycoproteins
including signaling receptors, where the sugars can have crit-
ical functions. The best-known example is that of selectin
ligands, which mediate leukocyte rolling on endothelial cells
(Ley, 2001). The discovery that Notch signaling involves fu-
cose-based glycans (Moloney et al., 2000) heralds another
exciting area in glycobiology, dubbed the “Cinderella sci-
ence” in 2001 (Alper, 2001). Before that time, studies
showed that stable fucosylated glycan expression in intestinal
epithelial cells requires continuous dialogue with the gut’s
commensal flora (Hooper and Gordon, 2001). In humans,
congenital disorder of glycosylation II-c (CDG-IIc)* caused
by mutations in the Golgi GDP-Fucose transporter results
in global fucosylation defects, profound mental retardation,
failure to thrive, recurrent infections, and leukocytosis
(Becker and Lowe, 1999; Freeze, 2001; Lübke et al., 2001).
GDP-Fucose is mostly derived from the de novo pathway
(Fig. 1). Mutant mammalian cell lines lacking the first
enzyme (GMD) in the pathway lose fucosylation, but this
does not affect their survival. Adding fucose to the medium
supplements the salvage pathway and corrects the glycosylation
defect (Fig. 1). Applying the same rationale, Smith et al.
(2002) knocked out the de novo pathway using homologous
recombination to ablate the FX gene in mice, and then at-
tempted to restore normal fucosylation with exogenous fucose.
Heterozygous matings generated an expected ratio of null
embryos at 3.5 d postcoitum (dpc). Significant losses occurred
by 12.5 dpc, but normal looking 18.5-dpc nulls contained
fucosyalted glycans similar to wild-type embryos. Fibroblasts
derived from the nulls could not synthesize fucosylated gly-
cans unless given a modest 22-uM exogenous fucose. Clearly,
the null embryos in utero obtained fucose from a maternal or
fraternal source via lysosomal catabolism of glycoconjugates or
direct import of the monosaccharide. Both routes are possible
since plasma membrane and lysosomal membrane fucose
transporters exist (Jonas et al., 1990; Wiese et al., 1994). Un-
fortunately, little is known about the availability, transport, or
utilization of exogenous monosaccharides in any mammalian
system, not to mention the embryonic environment.
Live pups died before, or soon after, weaning. Undaunted,
the research team shot-gunned the null allele into a series of
other strains hoping to generate viable progeny. Fortunately,
one approach produced two males that survived into adult life
when reared on fucose. These prized survivors were mated with
heterozygous females and produced a substantial proportion of
null pups (
 
 
 
30%). Surprisingly, fucose supplements during
gestation did not increase litter size or survival. Based on these
crosses, they concluded that one or more, yet to be identified,
genes accounted for this success. Recent and more selective
breeding produced an even greater percentage of null progeny.
FX null mice were small at weaning, but grew normally
when given fucose-supplemented water and chow. Without
fucose, null mice had excessive diarrhea, and the histopa-
thology of the colon resembled inflammatory bowel syn-
drome with crypt destruction, abscesses, and inflammatory
cell infiltrates. Providing fucose halted diarrhea within 9 d,
and withdrawing it provoked diarrhea again 
 
 
 
16 d later.
The reasons for this pathology are unknown, and this symptom
has not been reported in fucosylation-deficient CDG-IIc
patients. It is interesting to note that the development of
IBD in mouse models requires the participation of bacterial
flora (Kosiewicz et al., 2001), and that the types of bacteria
colonizing the intestine influence the glycosylation status of
the intestinal epithelial cells (Hooper and Gordon, 2001).
Some of the pathology may simply result from an imbalance
of fucose metabolizing organisms in the gastrointestinal
tract, since these organisms metabolize most of the fucose
given to normal mice (Bocci and Winzler, 1969). Therefore,
loss of fucose-catabolizing microbes might change the circu-
lating levels of fucose in null animals. Unfortunately, the
authors did not determine plasma fucose levels in the mice.
Selectin ligand synthesis in FX null mice requires exogenous
fucose, and without it, nulls have a 25-fold increase in circu-
lating leukocytes. Adding fucose dramatically decreases neu-
trophils within a few hours, and they are replaced by P-selectin–
binding cells. Somewhat later, E-selectin binding also appears.
The same dramatic disappearance of neutrophils and sequential
appearance of P- and E-selectins is also seen in CDG-IIc
patients given fucose (Marquardt et al., 1999). The preferential
reexpression of P-selectin binding may occur because effective
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binding to the P-selectin counter receptor, PSGL-1, requires
only a single fucosylated oligosaccharide.
Peripheral neutrophils drop within a few hours after giving
fucose, primarily due to increased turnover of circulating
cells that synthesize fucosylated counter receptors. In addi-
tion, and quite unexpectedly, fucosylated glycans also control
neutrophil proliferation. The ratio of myeloid to erythroid
(M/E) cells in the bone marrow is more than
 
 
 
twofold higher
than normal in FX null mice without fucose. Mature CFU-
GM
 
 
 
 myeloid cells are also more than twofold higher. They
normalize within 48 h on fucose, whereas erythroid precur-
sors and other pluripotent progenitors are not altered. The
M/E ratio of cells in the bone marrow takes another 48–96 h
to normalize, suggesting that fucosylated glycans regulate
granulocyte production. The mechanism is unknown, but
this is another example of glycan-mediated cell signaling
controlling cell proliferation and death (Lowe, 2001).
Withholding fucose again has the opposite effects: selectin
ligands disappear, neutrophils increase, and bone marrow
M/E ratio becomes abnormal again. The effects are more
gradual than when adding fucose, since turnover provides a
variable trickle of fucose for salvage.
The “fucose faucet” may provide a way to analyze when
and where fucosylated glycans are critical for Notch signal-
ing pathways involving lymphoid development, hemato-
poiesis, somitogenesis, and epithelial cell differentiation.
The modifier gene(s) permitting the survival of viable null
males may give insight into the fucosylation pathways. Mice
probably do not catabolize fucose, so improved fucose utili-
zation through fucose kinase, GDP-fucose pyrophosphory-
lase, the Golgi GDP-fucose transporter, or putative plasma
membrane fucose transporter (Wiese et al., 1994) may be
important. The recent identification of 14 human facilitated
diffusion monosaccharide transporter genes is far ahead of
their functional analysis (Joost and Thorens, 2001). Most of
the encoded proteins are assumed to transport glucose, but
their conserved domain structure and divergent amino acid
sequences give no clues about their monosaccharide specific-
ity. Some mouse orthologues of the human transporters will
probably carry fucose.
These studies show that, whereas glucose can generate all
sugars for glycoconjugate synthesis, it is not the only source. A
few CDG patients (Freeze, 2001) and FX mice show that di-
etary or salvaged sugars can make substantial contributions. Di-
rect utilization of other sugars might be important in less acute
situations. The controversial use of glucosamine to treat os-
teoarthritis (McAlindon et al., 2000) and N-acetylglucosamine
for colitis (Salvatore et al., 2000) may supplement normally mi-
nor biosynthetic pathways in chronically stressed cells.
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Figure 1. Fucose metabolism in mammalian cells. Fucose (blue 
triangle) is activated to GDP-Fucose in two ways. One is by conversion 
of GDP-Mannose via a two enzyme pathway (GMD and FX). 
Knocking out this pathway forces cells to rely on the other pathway 
where fucose enters the cell through a putative plasma membrane 
transporter, is converted to Fuc-1-P, and then to GDP-Fuc in the 
cytosol. A Golgi transporter delivers the donor to Golgi fucosyl 
transferases for synthesis of various glycoconjugates.